Administrative Supplement: COBRE in Pharmaceutical Research and Innovation

行政补充：COBRE 药物研究与创新

• 批准号: 10794454
• 负责人: Jon Scott Thorson
• 金额: $ 21.26万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10794454
• 关键词: Address; Administrative Supplement; Area; Award; Biology; Biomedical Research; Bone Regeneration; Cardiovascular Diseases; Centers of Research Excellence; Chemicals; Clinical; Collaborations; Communicable Diseases; Communication; Core Facility; Development; Devices; Discipline; Disease; Education; Environment; Faculty; Fostering; Funding; Goals; Health; Infrastructure; Institution; Kentucky; Malignant Neoplasms; Mentors; Mentorship; Modeling; Molecular Medicine; Organic Synthesis; Outcome; Parents; Pharmacologic Substance; Pharmacy facility; Phase; Productivity; Research; Research Personnel; Research Project Grants; Research Support; Science; Scientist; Testing; Therapeutic; Tissues; Translational Research; Translations; Universities; Validation; career development; clinical application; college; experience; faculty research; innovation; interdisciplinary collaboration; interest; multidisciplinary; pre-clinical; pre-clinical research; prevent; tool

SUMMARY/ABSTRACT OF PARENT AWARD (P20 GM130456) The Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation (CPRI) at the University of Kentucky (UK) is a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. This Phase I COBRE leverages and develops unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Key COBRE infrastructure to be developed and implemented in Phase I includes the CPRI Administrative Core and two research support cores (the Translational Core and the Computational Core) and the COBRE will also further develop and leverage the COBRE for Molecular Medicine’s Organic Synthesis Core to support CPRI junior faculty projects/pilots. CPRI currently supports four outstanding junior investigators working in three therapeutic areas (cancer, infectious disease and tissue/bone regeneration). Our overarching hypothesis is that CPRI’s translational chemical biology focus presents a distinctly unique UK platform to: i) engage, integrate and mentor junior faculty from a broad range of fundamental, applied and clinical disciplines; ii) facilitate the development of new impactful probes/tools/models and advance innovative transdisciplinary research; and iii) bridge the gap between basic academic research discoveries and commercial/clinical application via education, mentorship and key support infrastructure. CPRI’s distinct focus on translational chemical biology and early translation fills a notable preclinical research gap for many of UK’s exceptional research centers strategically focused on understanding, treating and preventing the major diseases that contribute to Kentucky’s disproportionate health challenges. Anticipated COBRE outcomes include an increase in the number and diversity of UK junior faculty engaged in translational chemical biology research and better-prepared to develop and employ innovative biomedical probes/tools/models/materials, new sustainable UK translational chemical biology research support infrastructure and capabilities, an increase in the number of UK junior faculty with independent research funding, and a boost in the number potentially ‘translatable’ UK preclinical assets.

家长奖摘要/摘要(P20 GM130456) 药学研究与创新生物医学研究卓越中心(CPRI) 肯塔基大学(英国)是一所专注于转化化学的综合性多学科中心 生物学[化学生物学的纽带(应用化学生物学原理开发有效的 探索/模型以促进我们对生物学的理解)和药学(应用 促进解决未得到满足的临床需求的线索/材料/装置的制药原则)]。此阶段I Cobre利用并开发独特的翻译化学生物学研究支持基础设施/专业知识 促进初级教师的指导和职业发展，创新的生物医学研究 探头/工具/模型/材料的开发和验证，以及潜在“可翻译”的早期进展 资产。将在第一阶段开发和实施的主要Cobre基础设施包括CPRI管理 核心和两个研究支持核心(翻译核心和计算核心)和科布雷将 还进一步开发和利用分子医学的有机合成核心来支持CPRI 初级教员项目/试点。CPRI目前支持四名优秀的初级调查人员在三个 治疗领域(癌症、传染病和组织/骨再生)。 我们的总体假设是，CPRI的翻译化学生物学重点呈现了一个明显独特的 英国平台：i)吸引、整合和指导来自广泛的基础、应用和 临床学科；ii)促进新的有效探头/工具/模型的开发并推进创新 跨学科研究；以及iii)弥合基础学术研究发现和 通过教育、指导和关键支持基础设施实现商业/临床应用。CPRI的鲜明重点 关于翻译化学生物学和早期翻译的研究填补了许多英国的临床前研究空白 特殊的研究中心战略性地专注于了解、治疗和预防重大疾病 这导致了肯塔基州不成比例的健康挑战。预期的Cobre结果包括 英国从事翻译化学生物学研究的初级教员的数量和多样性的增加 更好地准备开发和使用创新的生物医学探头/工具/模型/材料，新的可持续发展 英国翻译化学生物学研究支持基础设施和能力，数量增加 英国初级教员获得独立研究资金，并增加了潜在的可翻译英国教师的数量 临床前资产。